PSMB5 Gene
Introduction
The PSMB5 (Proteasome Subunit Beta 5) gene encodes the beta5 subunit of the 20S proteasome core particle, the principal proteolytic enzyme responsible for degrading ubiquitinated proteins in eukaryotic cells. Located at chromosomal position 14q11.2, PSMB5 is one of seven beta subunits that form the inner catalytic rings of the proteasome barrel. This gene encodes the chymotrypsin-like proteolytic activity, which is the primary activity responsible for protein degradation and is the target of the anti-cancer drug bortezomib.
title: PSMB5 Gene
<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | PSMB5 |
| Full Name | Proteasome Subunit Beta 5 |
| Chromosomal Location | 14q11.2 |
| NCBI Gene ID | [5693](https://www.ncbi.nlm.nih.gov/gene/5693) |
| OMIM | [177046](https://www.omim.org/entry/177046) |
| Ensembl ID | ENSG00000100814 |
| UniProt | [P28074](https://www.uniprot.org/uniprot/P28074) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Cancer |
</div>
Overview
...PSMB5 Gene
Introduction
The PSMB5 (Proteasome Subunit Beta 5) gene encodes the beta5 subunit of the 20S proteasome core particle, the principal proteolytic enzyme responsible for degrading ubiquitinated proteins in eukaryotic cells. Located at chromosomal position 14q11.2, PSMB5 is one of seven beta subunits that form the inner catalytic rings of the proteasome barrel. This gene encodes the chymotrypsin-like proteolytic activity, which is the primary activity responsible for protein degradation and is the target of the anti-cancer drug bortezomib.
title: PSMB5 Gene
<div class="infobox infobox-gene">
| | |
|---|---|
| Gene Symbol | PSMB5 |
| Full Name | Proteasome Subunit Beta 5 |
| Chromosomal Location | 14q11.2 |
| NCBI Gene ID | [5693](https://www.ncbi.nlm.nih.gov/gene/5693) |
| OMIM | [177046](https://www.omim.org/entry/177046) |
| Ensembl ID | ENSG00000100814 |
| UniProt | [P28074](https://www.uniprot.org/uniprot/P28074) |
| Associated Diseases | Alzheimer's Disease, Parkinson's Disease, Cancer |
</div>
Overview
Mermaid diagram (expand to render)
PSMB5 encodes the beta5 subunit of the 20S proteasome, also known as the LMP7 subunit in the immunoproteasome context. PSMB5 carries the chymotrypsin-like proteolytic activity, which cleaves after hydrophobic amino acid residues and is the rate-limiting step in protein degradation. This makes PSMB5 the most catalytically important subunit and the primary target of proteasome inhibitor drugs["@groll2000"].
The 20S proteasome is a 28-subunit protease organized as a four-ring stack. The two inner beta rings contain seven subunits each, with PSMB5, PSMB1, and PSMB2 providing the three catalytic activities: chymotrypsin-like (PSMB5), caspase-like (PSMB1), and trypsin-like (PSMB2)[@ciechanover2015].
Function
Proteasome Structure and Assembly
PSMB5 assembles with six other beta subunits to form the proteolytic beta rings:
- PSMB5 provides the primary chymotrypsin-like activity
- The subunit contains an N-terminal threonine residue that serves as the catalytic nucleophile
- PSMB5 expression can be induced by interferon-gamma in the immunoproteasome variant
Catalytic Mechanism
PSMB5 cleaves peptide bonds after hydrophobic residues (Phe, Leu, Trp, Tyr):
- Generates peptides for antigen presentation
- Degrades regulatory proteins involved in cell cycle, [apoptosis](/entities/apoptosis), and signaling
- Processes proteins tagged with polyubiquitin chains[@kisselev1999]
Neuronal Functions
In [neurons](/entities/neurons), PSMB5-mediated proteasome activity is critical for:
- Synaptic plasticity and activity-dependent protein turnover
- Degradation of misfolded proteins and protein aggregates
- Regulation of neuroprotective signaling pathways
- Mitochondrial protein quality control
- Clearance of disease-related proteins ([amyloid-beta](/proteins/amyloid-beta), [tau](/proteins/tau), alpha-synuclein)[@tai2010]
Disease Associations
Alzheimer's Disease
PSMB5 activity is significantly reduced in AD brain:
- Contributes to accumulation of amyloid-beta and tau aggregates
- Impaired degradation of ubiquitinated proteins
- Synaptic proteasome dysfunction correlates with cognitive decline
- Proteasome activity restoration is a therapeutic target[@gregori1995]
Parkinson's Disease
[alpha-Synuclein](/proteins/alpha-synuclein) degradation is dependent on proteasome activity:
- PSMB5 dysfunction contributes to Lewy body formation
- Reduced proteasome activity in substantia nigra of PD patients
- Gene therapy approaches targeting proteasome function under investigation[@mcnaught2002]
Cancer
PSMB5 is the primary target of proteasome inhibitor drugs:
- Bortezomib and carfilzomib bind to PSMB5
- Inhibit chymotrypsin-like activity and induce apoptosis
- Effective in multiple myeloma treatment[@adams2004]
Expression
PSMB5 is ubiquitously expressed with high levels in metabolically active cells:
- Brain: Expressed throughout [cortex](/brain-regions/cortex), [hippocampus](/brain-regions/hippocampus), [basal ganglia](/brain-regions/basal-ganglia), and [cerebellum](/brain-regions/cerebellum)
- Neuronal expression: High in pyramidal neurons and dopaminergic neurons
- Glial cells: Present in [astrocytes](/entities/astrocytes) and [microglia](/cell-types/microglia-neuroinflammation)
Therapeutic Implications
PSMB5 is a validated drug target:
- Proteasome inhibitors: Bortezomib, carfilzomib, ixazomib (approved for multiple myeloma)
- Proteasome activators: Potential approach for neurodegenerative diseases
- Gene therapy: Enhancing PSMB5 expression to boost proteasome activity[@schmidt2014]
Background
The study of Psmb5 Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
See Also
- [Proteasome](/mechanisms/ubiquitin-proteasome-system)
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [Protein Aggregation](/mechanisms/protein-aggregation-neurodegeneration)
- [PSMB5 Protein](/proteins/psmb5-protein)
External Links
- [NCBI Gene: PSMB5](https://www.ncbi.nlm.nih.gov/gene/5693)
- [UniProt: P28074](https://www.uniprot.org/uniprot/P28074)
- [Ensembl: ENSG00000100814](https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000100814)
References
[Keck et al., Proteasome in Neurodegenerative Diseases (2023) (2023)](https://doi.org/10.1016/j.neurobiolaging.2023.01.001)
[Groll et al., Structure of the 20S Proteasome (2000) (2000)](https://doi.org/10.1016/S0092-8674(00)
[Unknown, Ciechanover, The Ubiquitin-Proteasome Pathway (2015) (2015)](https://doi.org/10.1038/nrm4002)
[Kisselev et al., Proteasome Catalytic Sites (1999) (1999)](https://doi.org/10.1016/S0092-8674(00)
[Unknown, Tai & Schuman, Proteasome in Synaptic Plasticity (2010) (2010)](https://doi.org/10.1016/j.neuron.2010.04.012)
[Gregori et al., Proteasome Dysfunction in AD (1995) (1995)](https://doi.org/10.1006/exnr.1995.4456)
[McNaught et al., Proteasome Impairment in PD (2002) (2002)](https://doi.org/10.1001/jama.287.6.673)
[Unknown, Adams, Proteasome Inhibitors in Cancer (2004) (2004)](https://doi.org/10.1158/1078-0432.CCR-04-1171)
[Unknown, Schmidt & Finley, Proteasome Activators (2014) (2014)](https://doi.org/10.1016/j.tips.2014.08.003)Pathway Diagram
The following diagram shows the key molecular relationships involving PSMB5 Gene discovered through SciDEX knowledge graph analysis:
Mermaid diagram (expand to render)